Aura Biosciences, Inc.
80 Guest Street, 5th Floor
Cambridge
Massachusetts
02135
United States
Tel: 617-500-8864
Website: http://www.aurabiosciences.com/
90 articles about Aura Biosciences, Inc.
-
Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
3/27/2024
Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors to preserve the function of the afflicted organ with cancer, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided recent business highlights.
-
Aura Biosciences to Participate in Upcoming Investor Conferences - February 26, 2024
2/26/2024
Aura Biosciences Inc. today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences.
-
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma
12/7/2023
Aura Biosciences Inc. today announced the first patient has been dosed in the global Phase 3 CoMpass trial evaluating the safety and efficacy of bel-sar for the first-line treatment of adult patients with early-stage choroidal melanoma.
-
Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
11/9/2023
Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today reported financial results for the third quarter ended September 30, 2023, and provided clinical development and operational highlights.
-
Aura Biosciences to Participate in Upcoming Investor Conferences - November 8, 2023
11/8/2023
Aura Biosciences Inc. today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences.
-
Aura Biosciences Announces Pricing of Public Offering of Common Stock - November 07, 2023
11/7/2023
Aura Biosciences, Inc. announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $9.00 per share.
-
Aura Biosciences Announces Proposed Public Offering of Common Stock - November 06, 2023
11/6/2023
Aura Biosciences, Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, announced the launch of an underwritten public offering of its common stock.
-
Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma
11/6/2023
Aura Biosciences, Inc. (NASDAQ: AURA) today announced it has received agreement from the U.S. Food and Drug Administration (FDA) under an SPA for the design and planned analysis of CoMpass, the Company’s global Phase 3 clinical trial of bel-sar for the first-line treatment of adult patients with early-stage choroidal melanoma (CM).
-
Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023
10/31/2023
Aura Biosciences Inc. announced that updated data from the Phase 2 trial evaluating the safety and efficacy of suprachoroidal administration using its first VDC product candidate, bel-sar, for the first-line treatment of adult patients with early-stage choroidal melanoma will be presented at the upcoming American Academy of Ophthalmology 2023 Annual Meeting being held November 3-6, 2023, in San Francisco.
-
Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments
10/2/2023
Aura Biosciences Inc. announced the appointments of Jill Hopkins, M.D., as Chief Medical Officer, President of Research & Development, and Mark Plavsic, Ph.D., as Chief Technology Officer.
-
Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
8/9/2023
Aura Biosciences Inc. today reported financial results for the second quarter ended June 30, 2023, and provided clinical development and operational highlights.
-
Aura Biosciences to Participate in Upcoming Investor Conferences - May 24, 2023
5/24/2023
Aura Biosciences Inc. announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences: TD Cowen 4th Annual Oncology Innovation Summit on Tuesday, May 30, 2023.
-
Aura Biosciences to Participate in the JMP Securities Life Sciences Conference
5/12/2023
Aura Biosciences Inc. announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in a fireside chat at the JMP Securities Life Sciences Conference on Tuesday, May 16, 2023, at 2:00 p.m. ET.
-
Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights
3/15/2023
Aura Biosciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2022, and provided clinical development and operational highlights.
-
Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration
2/16/2023
Aura Biosciences, Inc. today announced the presentation of positive interim Phase 2 safety and efficacy data of bel-sar with 9-10 months of follow up evaluating two key clinical endpoints: tumor control and visual acuity preservation using the suprachoroidal (SC) route of administration for the first-line treatment of patients with early-stage choroidal melanoma (indeterminate lesions and small choroidal melanoma (IL/CM)).
-
Aura Biosciences to Participate in Upcoming Investor Conferences - February 9, 2023
2/9/2023
Aura Biosciences Inc. today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences.
-
Aura Biosciences Announces Pricing of Public Offering of Common Stock - December 01, 2022
12/1/2022
Aura Biosciences, Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, announced the pricing of an underwritten public offering of 6,700,000 shares of its common stock at a price to the public of $12.00 per share.
-
Aura Biosciences Announces Proposed Public Offering of Common Stock - November 30, 2022
11/30/2022
Aura Biosciences, Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, announced the launch of an underwritten public offering of its common stock.
-
Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma
11/10/2022
Aura Biosciences Inc. today announced that it has initiated startup activities for the global Phase 3 trial.
-
Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
11/10/2022
Aura Biosciences Inc. today reported financial results for the third quarter ended September 30, 2022 and provided clinical development and operational highlights.